Patents by Inventor Nicholas Marsh

Nicholas Marsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
    Publication number: 20210017252
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: August 6, 2020
    Publication date: January 21, 2021
    Inventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
  • Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
    Patent number: 10774130
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: September 15, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
    Publication number: 20180265572
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: January 10, 2018
    Publication date: September 20, 2018
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
  • Multivalent fibronectin based scaffold domain proteins
    Patent number: 9902762
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: February 27, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
    Publication number: 20140349929
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: March 28, 2014
    Publication date: November 27, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
  • Multivalent fibronectin based scaffold domain proteins
    Patent number: 8728483
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: May 20, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
    Publication number: 20130012435
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: June 26, 2012
    Publication date: January 10, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • Multivalent fibronectin based scaffold domain proteins
    Patent number: 8221765
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: July 17, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • COMBINATION OF VEGFR2 AND IGF1R INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
    Publication number: 20110123545
    Abstract: Methods for increasing endothelial cell apoptosis under hypoxic conditions in a patient undergoing a treatment that comprises an IGF1R inhibitor, the method comprising administering to the patient a VEGFR2 inhibitor
    Type: Application
    Filed: November 24, 2010
    Publication date: May 26, 2011
    Inventors: H. Nicholas Marsh, Irvith M. Carvajal, Marco M. Gottardis, Joan M. Carboni, Bryan C. Barnhart, Ricardo M. Attar
  • Imidazo[2,1-]-1,3,4-thiadiazole sulfonamides
    Patent number: 7772260
    Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: August 10, 2010
    Assignee: Aegera Therapeutics Inc.
    Inventors: James B. Jaquith, Gerald Villeneuve, Alain Boudreault, Stephen J. Morris, Jon Durkin, John W. Gillard, Kimberley E. Hewitt, H. Nicholas Marsh
  • Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides
    Patent number: 7741349
    Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Grant
    Filed: April 5, 2006
    Date of Patent: June 22, 2010
    Assignee: Aegera Therapeutics Inc.
    Inventors: James B. Jaquith, Gerald Villeneuve, Alain Boudreault, Stephen J. Morris, Jon Durkin, John W. Gillard, Kimberley Hewitt, H. Nicholas Marsh
  • MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
    Publication number: 20090299040
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: May 22, 2009
    Publication date: December 3, 2009
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: RAY CAMPHAUSEN, ERIC FURFINE, IRVITH M. CARVAJAL, H. NICHOLAS MARSH, MARCO GOTTARDIS, JOAN CARBONI, RICARDO ATTAR
  • GENE KNOCK-DOWN BY INTRACELLULAR EXPRESSION OF APTAMERS
    Publication number: 20090258425
    Abstract: Materials and Methods are provided for target validation by gene knock-down with intracellularly expressed aptamers and siRNAs. The aptamers produced by the materials and methods of the invention are useful in target validation for therapeutics development.
    Type: Application
    Filed: June 17, 2009
    Publication date: October 15, 2009
    Inventors: David Epstein, Harold Nicholas Marsh, Shannon Pendergrast, Kristin Thompson
  • Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
    Patent number: 7579450
    Abstract: The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: August 25, 2009
    Assignee: Archemix Corp.
    Inventors: Paula Burmeister, Sharon Cload, John L. Diener, Anthony Dominic Keefe, Sara Chesworth Keene, Markus Kurz, H. A. Daniel Lagassé, Harold Nicholas Marsh, Pooja Sawhney, Chunhua Wang
  • IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES
    Publication number: 20090042953
    Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Application
    Filed: April 7, 2008
    Publication date: February 12, 2009
    Applicant: AEGERA THERAPEUTICS, INC.
    Inventors: James B. JAQUITH, Gerald VILLENEUVE, Alain BOUDREAULT, Stephen J. MORRIS, Jon DURKIN, John W. GILLARD, Kimberley E. HEWITT, H. Nicholas MARSH
  • Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides
    Patent number: 7230019
    Abstract: This invention relates to compounds of Formula (I) and the use of compounds of Formula (I) as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: June 12, 2007
    Assignee: Aegera Therapeutics, Inc.
    Inventors: James B. Jaquith, Gerald Villeneuve, Alain Boudreault, Stephen Morris, Jon Durkin, John W. Gillard, Kimberly Hewitt, H. Nicholas Marsh
  • Aptamer therapeutics useful in ocular pharmacotherapy
    Publication number: 20040253243
    Abstract: The invention provides nucleic acid therapeutic compositions capable of binding to cytokines, growth factors and cell surface proteins, individually or in combinations of two or more, and methods for delivering these nucleic acid therapeutics in the treatment of glaucoma and other proliferative diseases of the eye.
    Type: Application
    Filed: January 21, 2004
    Publication date: December 16, 2004
    Inventors: David Epstein, Dilara Grate, Jeffrey Kurz, Nicholas Marsh, Thomas Greene McCauley, Charles Wilson